Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Regeneration Matrix is a French biotechnology company specializing in the development of advanced biomimetic scaffolds for tissue engineering and regenerative medicine. The company's core technology, "The Matrix," is a biological scaffold designed to mimic the natural extracellular matrix, facilitating the regeneration of complex tissues such as skin, bone, and blood vessels. By providing a structural and biochemical environment that promotes cell adhesion and proliferation, Regeneration Matrix aims to address critical needs in wound care and reconstructive surgery. The company's lead program, RM-Skin, is currently in clinical development for the treatment of chronic wounds and severe burns. Beyond dermatology, the company is exploring applications in orthopedics and vascular surgery to provide "off-the-shelf" regenerative solutions. Regeneration Matrix focuses on reducing the reliance on autografts and improving long-term patient outcomes through its innovative 3D scaffolding platform.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Regeneration Matrix.